|Tuberculosis and diabetes mellitus: convergence of two epidemics|
KE Dooley, RE Chaisson
The Lancet infectious diseases 9 (12), 737-746, 2009
|The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis|
K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ...
The lancet Respiratory medicine 5 (4), 291-360, 2017
|Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis|
KE Dooley, T Tang, JE Golub, SE Dorman, W Cronin
The American journal of tropical medicine and hygiene 80 (4), 634, 2009
RJ Wilkinson, U Rohlwink, UK Misra, R Van Crevel, NTH Mai, KE Dooley, ...
Nature reviews neurology 13 (10), 581-598, 2017
|TMC207: the first compound of a new class of potent anti-tuberculosis drugs|
A Matteelli, ACC Carvalho, KE Dooley, A Kritski
Future microbiology 5 (6), 849-858, 2010
|Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco|
KE Dooley, O Lahlou, J Knudsen, MD Elmessaoudi, I Cherkaoui, ...
BMC public health 11 (1), 1-7, 2011
|Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study …|
KE Dooley, P Sayre, J Borland, E Purdy, S Chen, I Song, A Peppercorn, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (1), 21-27, 2013
|Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis|
KE Dooley, J Golub, FS Goes, WG Merz, SR Timothy
Clinical infectious diseases 34 (12), 1607-1612, 2002
|Fluoroquinolone resistance in patients with newly diagnosed tuberculosis|
AS Ginsburg, N Hooper, N Parrish, KE Dooley, SE Dorman, J Booth, ...
Clinical infectious diseases 37 (11), 1448-1452, 2003
|World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?|
KE Dooley, EA Obuku, N Durakovic, V Belitsky, C Mitnick, ...
The Journal of infectious diseases 207 (9), 1352-1358, 2013
|Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine|
B Williamson, KE Dooley, Y Zhang, DJ Back, A Owen
Antimicrobial agents and chemotherapy 57 (12), 6366-6369, 2013
|Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial|
SE Dorman, RM Savic, S Goldberg, JE Stout, N Schluger, G Muzanyi, ...
American journal of respiratory and critical care medicine 191 (3), 333-343, 2015
|Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries|
KE Dooley, F Charles, AS Andrade
The Journal of infectious diseases 198 (7), 948-961, 2008
|Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug|
EM Svensson, S Murray, MO Karlsson, KE Dooley
Journal of Antimicrobial Chemotherapy 70 (4), 1106-1114, 2015
|Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis|
EM Svensson, F Aweeka, JG Park, F Marzan, KE Dooley, MO Karlsson
Antimicrobial agents and chemotherapy 57 (6), 2780-2787, 2013
|GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last|
NC Bahr, S Marais, M Caws, R Van Crevel, RJ Wilkinson, JS Tyagi, ...
Clinical Infectious Diseases 62 (9), 1133-1135, 2016
|Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection|
KE Dooley, P Denti, N Martinson, S Cohn, F Mashabela, J Hoffmann, ...
The Journal of infectious diseases 211 (2), 197-205, 2015
|Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study …|
KE Dooley, JG Park, S Swindells, R Allen, DW Haas, Y Cramer, F Aweeka, ...
Journal of acquired immune deficiency syndromes (1999) 59 (5), 455, 2012
|T-SPOT. TB responses during treatment of pulmonary tuberculosis|
S Ribeiro, K Dooley, J Hackman, C Loredo, A Efron, RE Chaisson, ...
BMC infectious diseases 9 (1), 1-9, 2009
|Designing drug trials: considerations for pregnant women|
JS Sheffield, D Siegel, M Mirochnick, RP Heine, C Nguyen, KL Bergman, ...
Clinical infectious diseases 59 (suppl_7), S437-S444, 2014